New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024
DOI: 10.1016/j.bbcan.2024.189220 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024. Verfasst von Hongjuan Yao und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Health and Multimorbidity; NHC Key Laboratory of Biotechnology for Microbial Drugs; Department of Oncology, Insti…. Hauptthemen laut MEDLINE: Smad4 Protein, Carcinoma, Pancreatic Ductal, Drug Resistance, Neoplasm, Pancreatic Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 133 Literaturangaben.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) patients have an unfavorable prognosis and disappointing treatment outcomes because of late diagnosis, high chemotherapy resistance, ineffective adjuvant chemotherapy, unavailable molecular targeted therapy, and profound immunosuppressive effects in the tumor microenvironment (TME). There are a variety of critical driver proteins, such as KRAS, TP53, PTEN and SMAD4, putatively involved in PDAC etiology. Current knowledge of their molecular mechanisms is still limited. SMAD4 gene alterations in ∼55 % of patients emphasize its key role in PDAC progression, metastasis, resistance and immunity. Despite extensive studies on the TGF-β/SMAD pathway, the impact of SMAD4 mutation/deficiency on PDAC prognosis and treatment, especially its mechanism in drug resistance, has not yet been elucidated. This review summarizes the latest advances in the effect of SMAD4 deficiency on the prognosis and therapeutic resistance of PDAC patients. It might be a predictive and prognostic biomarker or therapeutic target to achieve the desired clinical benefits. Moreover, we discuss potential strategies to implement targeted therapies in terms of SMAD4 genetic status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Respiratory Health and Multimorbidity; NHC Key Laboratory of Biotechnology for Microbial Drugs; Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences a…
- School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325000, China.
- Department of Neurobiology, Institute for Biological Research, "Siniša Stanković"- National Institute of the Republic of Serbia, University of Belgrade, Despota Stefana 142, 11060 Belgrade, Serbia.
- School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325000, China.. Electronic address: cailin@wmu.edu.cn.
Zitieren
APA
Yao, H., Luo, L., Li, R., Zhao, Y., Zhang, L., Pešić, M., Cai, L., & Li, L. (2024). New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2024.189220
Vancouver
Yao H, Luo L, Li R, Zhao Y, Zhang L, Pešić M, et al. New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024. doi:10.1016/j.bbcan.2024.189220
BibTeX
@article{Yao2024,
author = {Yao, Hongjuan and Luo, Liaoxin and Li, Rui and Zhao, Yelin and Zhang, Li and Pešić, Milica and Cai, Lin and Li, Liang},
title = {New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
doi = {10.1016/j.bbcan.2024.189220}
}
EUVIMED